Novo Nordisk (China) Pharmaceuticals Co., Ltd. (the “Company”) is committed to providing high quality drugs and to safeguarding patient safety. Recently the Company was contacted by some patients stating that the blood glucose was increasing after using insulin Penfill products. The suspected Penfills were bought in local pharmacies. Following an investigation, Novo Nordisk has identified that the suspected Penfill products are not produced by the Company but are counterfeits. Novo Nordisk has reported these incidents of counterfeit insulin Penfill to local regulatory authorities, and investigations are being carried out.
The Company reminds the customers to buy Novo Nordisk's products
from normal hospitals or pharmacies, instead of from any illegal
source. If you find any products to be suspected, please stop using it
and contact your local regulatory authorities immediately.